XML 115 R84.htm IDEA: XBRL DOCUMENT v3.24.1
Subsidiaries (Schedule of Subsidiaries) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disclosure of subsidiaries [line items]      
Current assets $ 1,096,041 $ 1,061,715  
Non-current assets 3,012,399 2,710,345  
Current liabilities (358,799) (192,978)  
Non-current liabilities (1,679,417) (1,283,164)  
Carrying amount of NCI 866,915 697,433  
Revenue 691,796 573,957 $ 487,763
Profit/(loss) after tax (210,948) 349,659 875,317
Profit/(loss) attributable to NCI 25,030 37,007 (54,956)
Cash flows from operating activities 276,788 771,381 240,529
Cash flows from investing activities (432,236) (203,438) (205,451)
Cash flows from financing activites excluding dividends paid to NCI 324,579 (493,676) 146,580
Effect of changes in the exchange rate on cash and cash equivalents (7,464) (13,640) 6,702
Net increase(decrease) in cash and cash equivalents $ 169,131 $ 74,267 $ 181,658
Opc Member      
Disclosure of subsidiaries [line items]      
NCI percentage [1] 59.88% 56.20% 53.14%
Current assets $ 460,810 $ 419,636 $ 346,380
Non-current assets 3,018,434 2,289,101 2,141,744
Current liabilities (353,735) (184,418) (230,518)
Non-current liabilities (1,679,847) (1,283,445) (1,341,962)
Net assets 1,445,662 1,240,874 915,644
Carrying amount of NCI 865,676 697,433 486,598
Revenue 691,796 573,957 487,763
Profit/(loss) after tax 46,955 65,352 (93,898)
Other comprehensive income (38,017) (11,249) 74,219
Profit/(loss) attributable to NCI 25,030 37,007 (54,022)
OCI attributable to NCI (24,624) (568) 33,661
Cash flows from operating activities 134,973 62,538 119,264
Cash flows from investing activities (594,303) (328,610) (256,200)
Cash flows from financing activites excluding dividends paid to NCI 503,245 285,898 311,160
Dividends paid to NCI 0 0 (10,214)
Effect of changes in the exchange rate on cash and cash equivalents (7,435) (13,545) 6,717
Net increase(decrease) in cash and cash equivalents $ 36,480 $ 6,281 $ 170,727
[1] The NCI percentage represents the effective NCI of the Group